Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-12-10 pm EST			5-day change	1st Jan Change
58.12 ^USD	-1.00%		-0.97%	+13.27%

Dec. 10	Agilent Cancer Diagnostic Assay Receives Certification to Comply with New EU Regulations	MT
Dec. 10	Berenberg Raises Price Target on Bristol-Myers Squibb to $60 From $55, Keeps Hold Rating	MT

Presenter SpeechTimothy Power (Executives)Well, good morning...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Bristol-Myers Squibb Company

Agilent Cancer Diagnostic Assay Receives Certification to Comply with New EU Regulations	Dec. 10	MT
Berenberg Raises Price Target on Bristol-Myers Squibb to $60 From $55, Keeps Hold Rating	Dec. 10	MT
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio At Ash 2024 with Long-Term Survival Data and Results from Expanding Pipeline	Dec. 09	CI
Nuvig Therapeutics, Inc. announced that it has received $161 million in funding from a group of investors	Dec. 04	CI
Bristol-Myers Seeks Bolt-On Acquisitions	Dec. 03	CI
Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM	Dec. 03
AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million	Dec. 03	CI
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	Nov. 29	MT
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating	Nov. 25	MT
Wall Street warms to AI's glow	Nov. 22
Bristol Myers: presents new data to ASH	Nov. 19	CF
Bristol Myers Squibb?s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	Nov. 19	CI
Bristol-Myers Squibb Company Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 09:30 AM	Nov. 19
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight	Nov. 18	MT
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating	Nov. 15	MT
Bristol-Myers Says European Committee Recommends Approval of Opdivo-Yervoy Combination Therapy for Colorectal Cancer	Nov. 15	MT
Bristol Myers Squibb's Augtyro Recommended for EU Approval	Nov. 15	MT
Bristol Myers: positive opinion from CHMP for Opdivo	Nov. 15	CF
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug	Nov. 15	DJ
Bristol-Myers Says European Committee Recommends Approval of Repotrectinib	Nov. 15	MT
Bristol Myers: positive opinion for repotrectinib in U	Nov. 15	CF
Bristol-Myers Squibb Faces $6.7 Billion Lawsuit in Renewed Cancer Drug Delay Case	Nov. 15	MT
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	Nov. 15	CI
JPMorgan Adjusts Price Target on Bristol-Myers Squibb to $70 From $64, Keeps Overweight Rating	Nov. 13	MT
Analyst recommendations: Spotify, Starbucks, Tesla, Block, Coinbase...	Nov. 13